Lupus & antiphospholipid syndrome
Comparison of a voclosporin-based triple immunosuppressive therapy to high-dose glucocorticoid-based immunosuppressive therapy: a propensity analysis of the AURA-LV and AURORA 1 studies and Aspreva Lupus Management Study (ALMS)
Authors' conclusion
Compared with the high-dose GC-based regimens used in ALMS, voclosporin-based triple immunosuppressive therapy resulted in fewer AEs overall and greater and earlier reductions in proteinuria over the first 6 months of treatment.
Study context
- Population
- Participants with active lupus nephritis (LN) in the AURA-LV, AURORA 1 and ALMS studies
- Participants
- 179 matched participants
- Comparison
- Voclosporin + mycophenolate mofetil (MMF) + low-dose glucocorticoid (GC) vs MMF or intravenous cyclophosphamide (IVC) with high-dose GC
Methodological detailspropensity score matching, pooled post hoc comparison of trial arms
- Propensity score matching
- Pooled post hoc comparison of trial arms
Primary result
As reported in the abstract
6 months
- Overall incidence of adverse events (AEs) higher in IVC- and MMF-treated participants of ALMS
- Significantly more voclosporin-treated participants achieved ≥25% reduction in urine protein creatinine ratio (UPCR) from baseline at 3 months and ≥50% reduction at 6 months
Further findings
Deaths · 6 months
Safety
AEs overall and by preferred term · 6 months
- Overall incidence of AEs higher in IVC- and MMF-treated participants of ALMS
- More voclosporin-treated participants reported glomerular filtration rate decreased, hypertension and anaemia
- Incidence of serious AEs similar across treatments
Original publication
Comparison of a voclosporin-based triple immunosuppressive therapy to high-dose glucocorticoid-based immunosuppressive therapy: a propensity analysis of the AURA-LV and AURORA 1 studies and ALMS. Lupus Sci Med. Published 9 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →